Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates.
Ontology highlight
ABSTRACT: In severe cases of COVID-19, glucocorticoid treatment improves clinical outcomes. However, in non-hospitalized patients, glucocorticoids have limited benefit and may impair viral control. The cell types regulated by glucocorticoids during SARS-CoV-2 infection are currently unknown. Here, we used rhesus macaques to examine the effects of glucocorticoids during the first 14 days of acute SARS-CoV-2 infection. Glucocorticoid treatment decreased local lung inflammation measured with 18FDG-PET/CT imaging. However, glucocorticoid treated animals also had evidence of elevated SARS-CoV-2 viral titers in the lower airways and pulmonary draining lymph nodes. Glucocorticoid treatment blunted plasmacytoid dendritic cell (pDC), eosinophil, innate-like CD8 T cell and early SARS-CoV-2 specific CD8 T cell responses in the airways. These data reveal the cell types that are directly impacted by immunosuppression with glucocorticoids and provide mechanistic insights into the discordant effects of glucocorticoids during SARS-CoV-2 infection.
ORGANISM(S): Macaca mulatta
PROVIDER: GSE294082 | GEO | 2026/02/03
REPOSITORIES: GEO
ACCESS DATA